Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I

Ito,Gentaro; Tanaka,Hiroaki; Ohira,Masaichi; Yoshii,Mami; Muguruma,Kazuya; Kubo,Naoshi; Yashiro,Masakazu; Yamada,Nobuya; Maeda,Kiyoshi; Sawada,Tetsuji; Hirakawa,Kosei

doi:10.3892/etm.2012.537

Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I

Authors:
- Gentaro Ito
- Hiroaki Tanaka
- Masaichi Ohira
- Mami Yoshii
- Kazuya Muguruma
- Naoshi Kubo
- Masakazu Yashiro
- Nobuya Yamada
- Kiyoshi Maeda
- Tetsuji Sawada
- Kosei Hirakawa
View Affiliations

Affiliations: Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Abeno-Ku, Osaka 545-8585, Japan
Published online on: April 2, 2012 https://doi.org/10.3892/etm.2012.537
Pages: 925-930

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein-bound polysaccharide K (PSK) is a glycoprotein that is purified from the mushroom Coriolus versicolor. In Japan, PSK is clinically used in combination with anticancer agents following gastric cancer surgery. Evaluation of the response is difficult, as efficacy is determined via antitumor immunoenhancing effects, and for that reason PSK has not become a standard therapy. The present study evaluated the expression of MHC class I in gastric cancer patients who received PSK postoperative adjuvant immunochemotherapy, and investigated the correlation between MHC class I expression and clinical outcomes. The subjects comprised 349 patients with stage II/III gastric cancer, who had received adjuvant therapy following curative resection between 1995 and 2008. MHC class I expression in the primary lesion was evaluated by immunohistochemical staining. Patients were divided into two treatment groups: one was only administered oral chemotherapy (chemotherapy-only group) and the other was administered chemotherapy plus PSK (PSK group). The clinical outcomes were compared between the two groups. The two groups did not differ in regard to their MHC class I expression. Expression-negative cases demonstrated 3-year recurrence-free survival (RFS) rates of 65% in the PSK group and 47% in the chemotherapy-only group. Therefore, the PSK group revealed a prolonged survival. For the 82 expression-negative cases with pN2 or greater, the RFS rates were 68% in the PSK group and 28% in the chemotherapy-only group, representing a significant difference. Thus, PSK adjuvant immunochemotherapy may be effective in MHC class I-negative patients, who are in a state of antitumor immunological tolerance, and patients with advanced lymph node metastasis of pN2 or greater.

View Figures

View References

1.	Sakuramoto S, Sasako M, Yamaguchi T, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Zhang H, Morisaki T, Matsunaga H, et al: Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs. Clin Exp Metastasis. 18:343–352. 2000.PubMed/NCBI
3.	Kanazawa M, Yoshihara K, Abe H, et al: Effects of PSK on T and dendritic cell differentiation in gastric or colorectal cancer patients. Anticancer Res. 25:443–449. 2005.PubMed/NCBI
4.	Zhang H, Morisaki T, Nakahara C, et al: PSK-mediated NF-kappaB inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1. Oncogene. 22:2088–2096. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study group of immunochemotherapy with PSK for gastric cancer. Lancet. 343:1122–1126. 1994. View Article : Google Scholar : PubMed/NCBI
6.	Cabrera T, Lara E, Romero JM, et al: HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother. 56:709–717. 2007. View Article : Google Scholar
7.	Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K and Aikou T: HLA-class I expression in gastric cancer. J Surg Oncol. 97:605–608. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Lee HW, Min SK, Ju YS, et al: Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5. J Gastrointest Surg. 15:1336–1343. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Liu Q, Hao C, Su P and Shi J: Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol. 44:960–969. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Shimada H, Okazumi S, Koyama M and Murakami K: Japanese Gastric Cancer Association Task Force for Research Promotion: Clinical utility of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 14:13–21. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P and Meyer HJ: Prognostic factors in gastric carcinoma. Results of the German gastric carcinoma study 1992. Cancer. 72:2089–2097. 1993. View Article : Google Scholar : PubMed/NCBI
12.	Sakcak I, Yildiz BD, Avsar FM, et al: Does N ratio affect survival in D1 and D2 lymph node dissection for gastric cancer? World J Gastroenterol. 17:4007–4012. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Kim JS, Kim MA, Oh DY, et al: Increasing nodal ratio is a poor prognostic factor for survival in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study. Jpn J Clin Oncol. 41:245–252. 2011.PubMed/NCBI
14.	Saito H, Fukumoto Y, Osaki T, et al: Prognostic significance of level and number of lymph node metastases in patients with gastric cancer. J Surg Oncol. 14:1688–1693. 2007. View Article : Google Scholar : PubMed/NCBI
15.	Funada T, Kochi M, Yamazaki S, Fujii M and Takayama T: Prognostic significance of a new system for categorization of the number of lymph node metastases in gastric cancer. Hepatogastroenterology. 58:642–646. 2011.PubMed/NCBI
16.	Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature. 411:380–384. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Mizukami Y, Kono K, Maruyama T, et al: Downregulation of HLA class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer. 99:1462–1467. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Seliger B, Hohne A, Knuth A, et al: Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res. 56:1756–1760. 1996.
19.	Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M and Durrant LG: Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut. 59:926–933. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Shen YQ, Zhang JQ, Miao FQ, et al: Relationship between the downregulation of HLA class I antigen and clinicopathological significance in gastric cancer. World J Gastroenterol. 11:3628–3631. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Lee TB, Min YD, Lim SC, et al: Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells. J Gastroenterol Hepatol. 17:32–38. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Zhou F: Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol. 28:239–260. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Vanky F, Wang P and Klein E: The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells. Cancer Immunol Immunother. 35:193–198. 1992. View Article : Google Scholar : PubMed/NCBI
24.	Pedrinaci S, Algarra I and Garrido F: Protein-bound polysaccharide (PSK) induces cytotoxic activity in the NKL human natural killer cell line. Int J Clin Lab Res. 29:135–140. 1999. View Article : Google Scholar : PubMed/NCBI
25.	Sakai T, Yamashita Y, Maekawa T, Mikami K, Hoshino S and Shirakusa T: Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm. 23:461–467. 2008. View Article : Google Scholar : PubMed/NCBI